Literature DB >> 22584870

Idiopathic pulmonary fibrosis is associated with circulating antiepithelial antibodies.

Ahmed Fahim1, Mei C Chong, Michael G Crooks, Simon P Hart.   

Abstract

PURPOSE: Idiopathic pulmonary fibrosis (IPF) is a restrictive fibrotic lung disease of uncertain etiology. Alveolar epithelial injury may be one of the inciting triggers in the pathogenesis of this disorder. We hypothesized that circulating antibodies to alveolar epithelial and endothelial cells may be involved in the pathogenesis of IPF.
METHODS: Antibodies to alveolar epithelial and endothelial cells were analyzed by indirect immunofluorescence using alveolar epithelial cells (A549) and human umbilical vein endothelial cells respectively. IgG and IgM antibodies in patients' serum were evaluated. Patterns of immunofluorescence, including membranous, cytoplasmic, and nuclear staining, were analyzed by fluorescence microscopy. The severity of immunofluorescence was divided into mild, moderate, and severe categories. Fifty-six patients (IPF = 28, non-IPF ILD = 9, non-ILD control = 19) were evaluated for antiepithelial antibodies, and 28 patients (IPF = 12, non-IPF ILD = 3, non-ILD control = 13) were studied for antiendothelial antibodies.
RESULTS: Compared with control subjects, serum from IPF patients displayed significantly higher IgG binding to alveolar epithelial cells (P = 0.041) with a membranous pattern of immunofluorescence. However, there was no significant difference in immunofluorescence with IgG on endothelial cells (P = 0.165). In terms of IgM antibodies, there was no differential fluorescence observed for either epithelial or endothelial cells.
CONCLUSIONS: There is evidence of increased IgG antibodies directed against alveolar epithelium in IPF. These antibodies may play a significant role in the pathogenesis of this fibrotic disorder. The findings of this study suggest further evaluation of the role of immune mediated alveolar epithelial injury in IPF.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22584870     DOI: 10.1007/s00408-012-9390-z

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  37 in total

1.  Detection of anti-ADAM 10 antibody in serum of a patient with pulmonary fibrosis associated with dermatomyositis.

Authors:  J Fujita; T Takeuchi; N Dobashi; Y Ohtsuki; M Tokuda; J Takahara
Journal:  Ann Rheum Dis       Date:  1999-12       Impact factor: 19.103

Review 2.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

3.  The role of anti-epithelial cell antibodies in the pathogenesis of bilateral radiation pneumonitis caused by unilateral thoracic irradiation.

Authors:  J Fujita; S Bandoh; Y Ohtsuki; N Dobashi; M Hiroi; T Takeuchi; Y Fukunaga; H Miyaue; S Onishi; T Ishida; J Takahara
Journal:  Respir Med       Date:  2000-09       Impact factor: 3.415

4.  Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis.

Authors:  Carol A Feghali-Bostwick; Christopher G Tsai; Vincent G Valentine; Stephen Kantrow; Michael W Stoner; Joseph M Pilewski; Aneal Gadgil; M Patricia George; Kevin F Gibson; Augustine M K Choi; Naftali Kaminski; Yingze Zhang; Steven R Duncan
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

5.  Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies.

Authors:  Cynthia M Magro; W James Waldman; Deborah A Knight; James N Allen; Tibor Nadasdy; Gwyn E Frambach; Patrick Ross; Clay B Marsh
Journal:  Hum Immunol       Date:  2006-04-05       Impact factor: 2.850

6.  Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.

Authors:  Ganesh Raghu; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Roland M du Bois; Joseph A Lasky; Michiel Thomeer; James P Utz; Rezaul K Khandker; Lawrence McDermott; Saeed Fatenejad
Journal:  Am J Respir Crit Care Med       Date:  2008-07-31       Impact factor: 21.405

7.  Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Sharon Safrin; Karen M Starko; Kevin K Brown; Paul W Noble; Ganesh Raghu; David A Schwartz
Journal:  Chest       Date:  2005-01       Impact factor: 9.410

8.  Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis.

Authors:  Camille Taillé; Sabine Grootenboer-Mignot; Céline Boursier; Laurence Michel; Marie-Pierre Debray; Jérôme Fagart; Lorena Barrientos; Arnaud Mailleux; Natacha Cigna; Florence Tubach; Joëlle Marchal-Sommé; Paul Soler; Sylvie Chollet-Martin; Bruno Crestani
Journal:  Am J Respir Crit Care Med       Date:  2010-10-08       Impact factor: 21.405

9.  The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis.

Authors:  Cynthia M Magro; James Allen; Amy Pope-Harman; W James Waldman; Patrick Moh; Susan Rothrauff; Patrick Ross
Journal:  Am J Clin Pathol       Date:  2003-04       Impact factor: 2.493

10.  Involvement of pulmonary endothelial cell injury in the pathogenesis of pulmonary fibrosis: clinical assessment by 123I-MIBG lung scintigraphy.

Authors:  Noriaki Takabatake; Tsuyoshi Arao; Makoto Sata; Shuichi Abe; Sumito Inoue; Yoko Shibata; Yasuchika Takeishi; Isao Kubota
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-23       Impact factor: 9.236

View more
  2 in total

Review 1.  The epithelium in idiopathic pulmonary fibrosis: breaking the barrier.

Authors:  Ana Camelo; Rebecca Dunmore; Matthew A Sleeman; Deborah L Clarke
Journal:  Front Pharmacol       Date:  2014-01-10       Impact factor: 5.810

2.  Intrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF.

Authors:  Ross Mills; Abhinav Mathur; Lisa M Nicol; Jeremy J Walker; Alexander A Przybylski; Alison C Mackinnon; Sarah E M Howie; William A H Wallace; Ian Dransfield; Nik Hirani
Journal:  J Immunol Res       Date:  2019-04-11       Impact factor: 4.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.